Leadership

Jacob Hooker, PhD

Chief Executive Officer

Colville Brown, MD

Chief Medical Officer

Alex Simon

Chief of Staff

Scientific founders

Stephen Haggarty, PhD

Co-Founder & Professor of Neurology, Harvard Medical School

Jacob Hooker, PhD

Co-Founder & Professor of Radiology, Harvard Medical School

Jerrold Rosenbaum, MD

Co-Founder & Chair Emeritus, Massachusetts General Hospital (MGH) Department of Psychiatry

Board of Directors

Simba Gill, PhD

Executive Chairman, Former CEO, Evelo Biosciences

Jacob Hooker, PhD

President & CEO, Sensorium

Ryan Katz

Founding Partner, Route 66 Ventures

Kevin Lalande, MBA

Founder & Managing Partner, Sante Ventures

Chaya D. Patel, PhD

Partner, Mission BioCapital

Jerrold Rosenbaum, MD

Co-Founder & Chair Emeritus, Massachusetts General Hospital (MGH) Department of Psychiatry

Dick Simon, MBA

Co-Founder

Investors

Scientific and clinical advisors

Huda Akil, PhD

Research Professor, University of Michigan Medical School

Andrew Cutler, MD

CMO, Neuroscience Education Institute

Maurizio Fava, MD

Psychiatrist-In-Chief, Department of Psychiatry, Massachusetts General Hospital

Douglas Feltner, MD

Chief Medical Officer, Neurosterix

Charles Green, PhD

Professor of Pediatrics and Psychiatry, UT Health Houston

K. Ranga Krishnan, MBBS

Professor Emeritus, Duke University

Sanjay J. Mathew, MD

Department Head, Psychiatry and Behavioral Sciences, Texas A&M College of Medicine

Charles B. Nemeroff, MD, PhD

Chair and professor with the Department of Psychiatry and Behavioral Sciences, UT Austin Dell Medical School

Raymond Sanchez, MD

Senior Advisor, Bain Capital Life Sciences

Murray B Stein MD, MPH, FRCPC

Distinguished Professor of Psychiatry and Public Health at the University of California San Diego

Jeffrey Strawn, MD

Professor of Psychiatry and Pediatrics, University of Cincinnati

Sensorium Therapeutics is a clinical stage biotechnology company developing brain and mental health treatments that are derived from nature, mechanistically driven, clinically precise, and designed to help people thrive. Its proprietary SensAI™ platform integrates artificial intelligence, chemistry, and neuroscience to mine more than 50 million curated relationships across biology, pharmacology, clinical outcomes, and human experience to unlock broader and derisked starting points for CNS drug discovery. SensAI has produced three differentiated programs in under three years—led by SENS-01, a first-in-class compound under investigation for the treatment of anxiety disorders—and built a robust IP estate extending into the 2040s.

Built for this moment

Leadership

Scientific founders

Board of Directors

Investors

Scientific and clinical advisors

Team

‍Contact

‍News